Topotecan Side Effects
It is possible that some side effects of topotecan may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to topotecan: oral capsule
Other dosage forms:
As well as its needed effects, topotecan may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking topotecan, check with your doctor immediately:More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- chest pain
- lower back or side pain
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- shortness of breath
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swollen glands
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
Some topotecan side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- hair loss or thinning of the hair
- lack or loss of strength
- loss of appetite
- weight loss
For Healthcare Professionals
Applies to topotecan: intravenous powder for injection, intravenous solution, oral capsule
Use of granulocyte colony stimulating factor (G-CSF) may be useful. Alternatively, dose reductions could be considered, especially if topotecan is used for palliative effects.
Risk of myelosuppression is increased in cases of pretreatment chemotherapy and/or radiation therapy.
Hematologic side effects have been the most profound and dose-limiting toxicity. Virtually all patients have developed neutropenia (80% to 98% less than 1,500/mm3), leukopenia (98% less than 3,000/mm3), anemia (85% to 95% less than 10 g/dL), and thrombocytopenia (44% to 63% less than 100,000/mm3). Twenty-five percent to 80% of patients developed severe pancytopenia. Nadirs have typically been observed 8 to 15 days after administration, with recovery often noted by day 21. During postmarketing use of topotecan, severe bleeding in association with thrombocytopenia has been reported.
Gastrointestinal side effects have been common, but rarely severe, and can usually be controlled with antiemetic therapy. Gastrointestinal side effects have included nausea (64%), vomiting (45%), diarrhea (32%), constipation (29%), abdominal pain (22%), stomatitis (18%), and anorexia (19%). Postmarketing reports of abdominal pain may potentially be associated with neutropenic colitis.
Gastrointestinal side effects have been reported to usually be mild to moderate in severity, observed seven to fourteen days after administration, and last for two to five days. Protracted cases of nausea, vomiting, or diarrhea have been reported infrequently. However, these data are from studies where antiemetic therapy was not routinely used, and effective antiemetic therapy is now available.
Abdominal pain potentially associated with neutropenic colitis has been reported.
Pain includes body pain, back pain, an skeletal pain.
General side effects have included fatigue (29%), fever (28%), pain (23%), and asthenia (25%).
Rash also includes pruritus, rash erythematous, urticaria, dermatitis, bullous eruption, and rash maculopapular.
Dermatologic side effects have included alopecia (49%) and rash (16%). During postmarketing use of topotecan, angioedema, severe dermatitis and severe pruritus have been reported.
Some of the reports of interstitial lung disease have been fatalities.
Respiratory side effects have included dyspnea (22%), coughing (15%), and interstitial lung disease. A case of bronchiolitis has also been reported.
Nervous system side effects have included headache (18%).
Musculoskeletal side effects have included arthralgias and myalgias.
Genitourinary side effects have been limited to rare cases of acute renal failure, microscopic hematuria, proteinuria, and dysuria.
Cases of acute renal failure have been associated with myelosuppression and sepsis. They are not necessarily directly caused by topotecan therapy.
Hypersensitivity reactions have included anaphylactoid reactions, angioedema, severe dermatitis, and severe pruritus.
Local side effects including erythema and bruising have resulted from inadvertent extravasation.
More about topotecan
- Other brands: Hycamtin
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.